Terns Pharmaceuticals Inc
NASDAQ:TERN
Terns Pharmaceuticals Inc
NASDAQ:TERN
Price:
52.63
USD
0.13%
Market Cap:
$5.6B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Terns Pharmaceuticals Inc
NASDAQ:TERN
|
US |
|
L
|
Leeds Group PLC
LSE:LDSG
|
UK |
|
Priority Technology Holdings Inc
NASDAQ:PRTH
|
US |
|
Shun Ho Holdings Ltd
HKEX:253
|
HK |
|
A
|
Asuransi Maximus Graha Persada Tbk PT
IDX:ASMI
|
ID |
|
G
|
George Kent (Malaysia) Bhd
KLSE:GKENT
|
MY |
|
Bank KB Bukopin Tbk PT
IDX:BBKP
|
ID |
|
G
|
Geumhwa PSC Co Ltd
KOSDAQ:036190
|
KR |
|
Hiliks Technologies Ltd
BSE:539697
|
IN |
|
T
|
Tangshan Sunfar Silicon Industries Co Ltd
SSE:603938
|
CN |
|
Securitas AB
STO:SECU B
|
SE |
|
T
|
Tony G Co-Investment Holdings Ltd
CNSX:TONY
|
CA |
Multiples-Based Value
The Multiples-Based Value of one
TERN
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 52.63 USD,
Terns Pharmaceuticals Inc
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TERN Multiples-Based Value
LOCKED
Multiples Across Competitors
TERN Competitors Multiples
Terns Pharmaceuticals Inc Competitors
Terns Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Terns Pharmaceuticals Inc
NASDAQ:TERN
|
5.9B USD | 0 | -61.4 | -44.5 | -44.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
887.6B USD | 13.5 | 42.7 | 28.8 | 30.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.2B USD | 6 | 21.2 | 14.8 | 18.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236.2B GBP | 5.2 | 30.1 | 16.6 | 23.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.5 | 11.6 | 13 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.5B USD | 4.5 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.6B CHF | 5.2 | 20.8 | 12.9 | 16.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.4 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.1B USD | 2.4 | 19.6 | 7.6 | 10.1 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
88.7B GBP | 2.7 | 15.5 | 8.4 | 10.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
